Author

Anne Phelan

BenevolentAI (United Kingdom)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:protein structure· 1

Frequent Co-Authors

Allan Christian ShawiD· 1 shared Amy F. A. KeerieiD· 1 shared Chloe F. AlleniD· 1 shared Daniel P. SmithiD· 1 shared David W. SheppardiD· 1 shared Heledd Brown-WrightiD· 1 shared Laura FerraiuoloiD· 1 shared Matthew J. StopfordiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Allan Christian ShawORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Artificial intelligence-augmented drug discovery identifies gefitinib as a potential treatment for ALS

Monika A. Myszczynska, Matthew J. Stopford, Nóra M. Márkus, Sophie Nyberg, Nicole L. Stone, Sarah M. Granger, Allan Christian Shaw, Raquel Rua Martins, Chloe F. Allen, Amy F. A. Keerie, Tyler R. Wells, Ruth H.E. Thomas, Heledd Brown-Wright, David W. Sheppard, Anne Phelan, , Laura Ferraiuolo

This paper uses AI to identify gefitinib as a potential ALS treatment, showing it protects motor neurons and reduces TDP-43 fragments in vitro and in vivo.

bioRxiv · Mar 6, 2025 · PreprintNeuroscience